| Previous Close | 0.0785 |
| Open | 0.0740 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0740 - 0.0785 |
| 52 Week Range | 0.0400 - 0.1400 |
| Volume | 835,316 |
| Avg. Volume | 707,880 |
| Market Cap | 65.93M |
| Beta (5Y Monthly) | 0.98 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0030 |
| Earnings Date | Aug 07, 2020 - Aug 11, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
Conference Call Scheduled for Tuesday, June 30th at 11:30 AM EDT NORTHVALE, NJ / ACCESSWIRE / June 29, 2020 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a ...
Financials for Fiscal Year Ended March 31, 2020 will be released June 29, 2020 NORTHVALE, NJ / ACCESSWIRE / June 24, 2020 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), ...
NORTHVALE, NJ / ACCESSWIRE / March 31, 2020 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP) a specialty pharmaceutical company developing niche generic products, ...
Q3 2020 Elite Pharmaceuticals Inc Earnings Call
Conference Call Scheduled for Tuesday, February 11th at 11:00 AM EST NORTHVALE, NJ / ACCESSWIRE / February 10, 2020 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), ...
Financials for Third Quarter Fiscal Year 2020 Ended December 31, 2020 will be released February 10, 2020 NORTHVALE, NJ / ACCESSWIRE / February 6, 2020 / Elite Pharmaceuticals, Inc. ("Elite" or ...
NEW YORK, NY / ACCESSWIRE / January 9, 2020 / Levi & Korsinsky announces it has commenced an investigation of Elite Pharmaceuticals, Inc. (OTCQB:ELTP) concerning possible breaches of fiduciary duty. To ...
NORTHVALE, NJ / ACCESSWIRE / December 12, 2019 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing its own generic products, ...
Conference Call Scheduled for Wednesday, November 13th at 11:00 AM EST NORTHVALE, NJ / ACCESSWIRE / November 12, 2019 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), ...
Financials for Second Quarter Fiscal Year 2020 Ended September 30, 2019 will be released November 12, 2019 NORTHVALE, NJ / ACCESSWIRE / November 6, 2019 / Elite Pharmaceuticals, Inc. ("Elite" ...
NORTHVALE, NJ / ACCESSWIRE / September 12, 2019 / Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for a generic version of Tylenol® with Codeine (acetaminophen and codeine phosphate) 300mg/15mg, 300mg/30mg, and 300mg/60mg tablets. Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company which is developing a pipeline of proprietary pharmacological abuse-deterrent opioid products as well as niche generic products. Elite specializes in oral sustained and controlled release drug products which have high barriers to entry.
NORTHVALE, NJ / ACCESSWIRE / August 9, 2019 / Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, announced results for the first quarter of fiscal year 2020 ended June 30, 2019 (“First Quarter”). Consolidated revenues for the First Quarter were $3.4 million, an increase of approximately 55% as compared to revenues for the comparable quarter of the prior fiscal year. The increase in revenues was largely attributed to revenues from the two products launched during the First Quarter, generic immediate release Adderall® and Dantrolene Capsules as well as continued growth in sales of Naltrexone tablets.
NORTHVALE, NJ / ACCESSWIRE / August 7, 2019 / Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that the first quarter financial results of the 2020 fiscal year will be released on Friday, August 9, 2019. Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company which is developing a pipeline of proprietary pharmacological abuse-deterrent opioid products as well as niche generic products. Elite owns generic products which have been licensed to TAGI Pharma, Glenmark Pharmaceuticals, Inc., USA., and Lannett Company, Inc. Elite currently has twelve approved generic products, four generic products filed with the FDA, one approved generic products pending manufacturing site transfer, and an NDA filed for SequestOx™.